A Study to Assess 7/8 HLA-matched Hematopoietic Stem Cell Transplantation Participants Treated With or Without Abatacept in Combination With a Calcineurin Inhibitor and Methotrexate

Completed

Conditions studied: Stem Cell Transplantation

In brief

The purpose of this study is to estimate overall survival (OS) for participants treated with abatacept versus those not treated with abatacept prior to hematopoietic stem cell transplantation (HSCT). Participants were included if their donors were unrelated and had 1-allele mismatched human leukocyte antigen (HLA) status.

Key facts

Study ID

NCT05421299

Run by

Bristol-Myers Squibb

People needed

378

Starts

2019-09-16

Expected to finish

2021-02-15

Last updated by the study team

2022-06-16

Who can join

Age: 6 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants who underwent first allogenic transplant in the US
• Participants with an unrelated donor who are HLA-matched at 7/8 loci (A, B, C, DRB1)
• Participants at least 6 years old with weight at least 20 kilograms
• Participants with a Karnofsky/Lansky Performance Score ≥80%
• Participants whose first allogeneic transplant occurred from January 1, 2011 to December 31, 2018
• Participants with any of the following diseases: AML, ALL, CML, MDS, HL, NHL
• Participants with any of the following graft versus host disease (GVHD) prophylaxis treatments:
• CNI plus MTX (with or without ATG and with or without abatacept); or
• Post-transplant cyclophosphamide (PT-Cy) without antithymocyte globulin (ATG)
• Participants treated with any of the following conditioning regiments: total body irradiation (TBI)/cyclophosphamide (Cy), busulfan (Bu)/Cy, Bu/fludarabine (flu), Flu/Melphalan (MEL)

You may not qualify if…

• Participants with missing information on ATG (yes/no)
• Participants receiving alemtuzumab (Campath)
• Participants with cord blood grafts
• Participants with non-MDS myeloproliferative disorders (NOTE: Participants with chronic myelomonocytic leukemia [CMMoL] will be included)
• Participants who did not consent to participate in research
• Participants treated at embargoed centers for research
• Participants treated with abatacept and ATG
• Among non-abatacept treated participants, participants transplanted at centers with abatacept trial participants
• Participants with any of the following missing propensity score variables:
• Disease status at transplantation (early, intermediate, advanced HL and NHL-chemosensitive)
• Age
• Gender (male, female)
• HSCT graft source (bone marrow [BM], peripheral blood [PB])
• Conditioning intensity (myeloablative, non-myeloablative / reduced intensity)
• Karnofsky/Lansky Performance Score (80%, 90-100%)
• CNI type (tacrolimus, CsA)

Where it is running

• Local Institution — Princeton, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.